文 献 9）Tan MCC, Ortega-Legaspi JM, Cheng SF, Patton KK. Acute myocarditis following high-dose interleukin-2 treatment. J Cardiol Cases 2017; 15: 28-31.10）Eisner RM, Husain A, Clark JI. Case report and brief review: IL-2-induced myocarditis. Cancer Invest 2004; 22: 401-4.11）Ma P, Liu J, Qin J, Lai L, Heo GS, Luehmann H, et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation 2024; 149: 48-66. 12）Zhu H, Galdos FX, Lee D, Waliany S, Huang YV, Ryan J, et al. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation 2022; 146: 316-35.13）Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, et al. 68 Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother cancer 2021; 9: e003594.14）Siebel C, Lendahl U. Notch signaling in development, tissue homeostasis, and disease. Physiol Rev 2017; 97: 1235-94.15）Borggrefe T, Oswald F. The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009; 66: 1631-46.16）Li S, Xu DZ, Murakoshi N, Yuan Z, Imaoka T, Tajiri K. Autoantibody profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study. Front Immunol 2024; 15: 1423622.17）Li S, Tajiri K, Ishizuka Y, Murakata Y, Yuan Z, Xu D, et al. Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study. Mol Biol Rep 2025; 52: 983. 1）Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol 2018; 48: 7-12. 2）Wang M, Zhai X, Li J, Guan J, Xu S, Li YY, et al. The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Front Immunol 2021; 12: 670391. 3）Schindler H, Lusky F, Daniello L, Elshiaty M, Gaissmaier L, Benesova K, et al. Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors. Front Oncol 2022; 12: 1010660. 4）Mone K, Reddy J. The knowns and unknowns of cardiac autoimmunity in viral myocarditis. Rev Med Virol 2023; 33: e2478. 5）Asatryan B, Asimaki A, Landstrom AP, Khanji MY, Odening KE, Cooper LT, et al. Inflammation and immune response in arrhythmogenic cardiomyopathy: State-of-the-art review. Circulation 2021; 144: 1646-55. 6）Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 2023; 29: 3100-10. 7）Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 2019; 140: 80-91. 8）Talele NP, Kumra H, Gomes-Santos IL, Ho WW, Andersson P, Siwicki M, et al. IL-1 β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity. J Immunother Cancer 2025; 13: e011404. 免疫チェックポイント阻害薬関連心筋炎のサイトカイン・自己抗体プロファイリング21
元のページ ../index.html#35